Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

2019: CRISPR and therapeutic gene editing comes of age

Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?

- PMLiVE

The 10-year Web Challenge

Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space.

Page & Page Health

- PMLiVE

Big opportunities in big data, but EMA and industry just getting started

250m genomes sequenced, but data trapped in silos

Bayer symbol

Bayer, Orion prep challenge in prostate cancer market

New arrival will face tough competition, not least generic Zytiga

- PMLiVE

CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts

- PMLiVE

UCB signs research deal with King’s College London

Company and academic researchers to share one facility

Downloadable Pack: Understanding Multiple Sclerosis

Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry.

Blue Latitude Health

- PMLiVE

Cutting through the noise: CRISPR

AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery

Going digital

Medical devices, Medicine 2.0 and beyond

Lighthouse Medical Communications US appoints Lisa Druce as its new Managing Partner

Lighthouse Medical Communications US, a Lucid Group company, is delighted to announce the appointment of its new Managing Partner, Lisa Druce.Lisa is an experienced strategic business leader and healthcare communications...

Lucid Group Communications Limited

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links